CN102551073B - Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition - Google Patents
Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition Download PDFInfo
- Publication number
- CN102551073B CN102551073B CN2012100412784A CN201210041278A CN102551073B CN 102551073 B CN102551073 B CN 102551073B CN 2012100412784 A CN2012100412784 A CN 2012100412784A CN 201210041278 A CN201210041278 A CN 201210041278A CN 102551073 B CN102551073 B CN 102551073B
- Authority
- CN
- China
- Prior art keywords
- lactoferrin
- nutritional composition
- lactoalbumin
- ala
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 44
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 44
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 44
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 44
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 44
- 235000016709 nutrition Nutrition 0.000 title abstract 10
- 239000000843 powder Substances 0.000 claims description 35
- 238000012856 packing Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 14
- 235000020256 human milk Nutrition 0.000 abstract description 10
- 210000004251 human milk Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 229940088592 immunologic factor Drugs 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract 4
- 239000000367 immunologic factor Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000003797 essential amino acid Substances 0.000 description 5
- 235000020776 essential amino acid Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000003024 peritoneal macrophage Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 235000008098 Oxalis acetosella Nutrition 0.000 description 3
- 241001119526 Paullinia Species 0.000 description 3
- 235000010240 Paullinia pinnata Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 241000024188 Andala Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101710126949 Lysin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a nutritional composition or food containing alpha-lactoalbumin and lactoferrin and application of the nutritional composition or the food. The nutritional composition contains the alpha-lactoalbumin and the lactoferrin in a weight ratio of (1:99)-(99:1). The invention also provides the application of the nutritional composition or the food containing the alpha-lactoalbumin and the lactoferrin to the strengthening of immunity. The alpha-lactoalbumin and the lactoferrin which have the specific content are contained in the nutritional composition containing the alpha-lactoalbumin and the lactoferrin, and are close to immune factors in human milk. By supplementing an immune essence which is close to breast milk in vitro, the nutritional composition has the effects of effectively improving the resistance and immunity of infants, and effectively improves the immunity of the kind of crowd. The invention has the advantages that: the nutritional composition is high in safety, has a good effect, and does not have toxic or side effect after being taken for a long time. The nutritional composition can be taken as food or a health-care product, can be used for a long time, and can bring a good social benefit.
Description
Technical field
The present invention relates to a kind of alimentation composition, more particularly, relate to a kind of alimentation composition and application in bread and cheese, health products or medicine thereof that contains ALA and lactoferrin.
Background technology
Because the more late ability of infant's immune system is full-fledged, so its immunity and resistance are all more weak, anti-infectious ability is poor, and a lot of infants can occur that gastrointestinal function, immunologic function imperfection, Abwehrkraft des Koepers are weak, the disorders of digestion, and infectious diseases etc.This has not only hindered the g and D of baby's physique, and the growth of baby's intelligence cognition, the growth of emotion sociability are all brought to impact in various degree.
Existing product such as colostrum of building up resistance for the infant on market, contain antibiotic medicine etc. and all have such-and-such drawback: as colostrum, contain hormone, possible induced precocity; The antibiotics long-term taking has certain toxic and side effect, particularly infant's normal development is had to adverse influence.
Lactoferrin (lactoferrin is called for short LF) is a kind of natural glycoprotein with immunologic function, by transferrins, is changed, and also someone is called " Lactoferrin ", mainly is present in breast milk and cow's milk.The content of lactoferrin in human milk is abundant especially, in first Ruzhong, can reach 7g/L especially.Along with its content of maturation of milk can descend to some extent, be the lg/L left and right during suckling.Content is lower in cow's milk, is only generally 0.1g/L, and content is much lower than breast milk.
ALA is present in all mammiferous milk, and it is the main protein in human milk, and ALA is conducive to improve the conversion of digesting and assimilating, promote lactose and improves cognitive ability.The concentration of ALA is 0.2-0.3g/100ml in human milk, accounts for the 10-20% of total protein, compares, and in cow's milk, only accounts for the 2-5% of total protein.Data shows, the nutritive quality of ALA, higher than the milk protein of standard, is not only because it contains the essential amino acid that content is high, also has conditionally essential amino acid.ALA more can combine with micronutrient.But according to present existing lactalbumin and Casilan, the meals that need to limit specific proteins for the infant also can not improve the amino acid composition that its protein is prepared burden.Future development may be used the essential amino acid part that in specific proteins composition supplement formula, protein lacks.For reaching the optimum protein of these purposes, it is the ALA in lactalbumin.
Summary of the invention
The purpose of this invention is to provide a kind of alimentation composition and application in bread and cheese, health food or medicine thereof that contains ALA and lactoferrin.This alimentation composition can effectively improve infant's resistance and immunity, and near the human milk immune factor.
Technical scheme of the present invention is:
A kind of alimentation composition that contains ALA and lactoferrin, comprise ALA and lactoferrin, and in described composition, the percentage by weight of ALA and lactoferrin is 1: 99-99: 1.
As preferably, in described composition ALA and the ratio of lactoferrin be 1: 50-50: 1.
As preferably, in described composition ALA and the ratio of lactoferrin be 1: 25-25: 1.
As preferably, in described composition ALA and the ratio of lactoferrin be 1: 10-10: 1.
As preferably, in described composition ALA and the ratio of lactoferrin be 1: 3-3: 1.
A kind of alimentation composition that contains ALA and lactoferrin, formulation is solid beverage, tablet, soft capsule, hard shell capsules, microcapsules, granule, beverage, pulvis or dairy products, comprise the described alimentation composition of above-mentioned any one, described alimentation composition accounts for the 1%-100% of finished product gross mass.
As preferably, described alimentation composition accounts for the 10%-90% of finished product gross mass.
As preferably, described alimentation composition accounts for the 15%-80% of finished product gross mass.
As preferably, described alimentation composition accounts for the 20%-70% of finished product gross mass.
As preferably, described alimentation composition accounts for the 30%-60% of finished product gross mass.
The above-mentioned alimentation composition that contains ALA and lactoferrin, the application aspect enhancing immunity.
Beneficial effect of the present invention is as follows:
Drawback according to existing product, especially for infant crowd, the invention provides a kind of alimentation composition that comprises ALA and lactoferrin, in the described alimentation composition that contains ALA and lactoferrin, the ALA and the lactoferrin that comprise certain content, near the human milk immune factor.By external immune elite of supplementing near breast milk, demonstrate the effect that better effectively improves infant's resistance and immunity, effectively improve such crowd's immunity.
It is good that described alimentation composition has a security, effective and advantage that long-term taking is without any side effects.
Described alimentation composition can be used as bread and cheese, health products or medicine, is suitable for long-term use, will bring good social benefit.
The specific embodiment
The invention will be further described below by following examples, and it will help to understand the present invention, but do not limit content of the present invention.
Embodiment 1 (hard shell capsules)
By ALA powder 1%; Lactoferrin powder 99%; After mixing in proportion, with capsule filling machine, fill, obtain.
Embodiment 2 (pulvis)
By ALA powder 1.2%; Lactoferrin powder 60%; Vitamin C 0.2%; Fruit powder 4.6%; FOS 34%; After mixing in proportion, carry out packing, obtain.
Embodiment 3 (granule)
By ALA powder 2.7%; Lactoferrin powder 67.5%; Lactose 29.8%; After mixing in proportion, through granulating, after drying, then carry out packing, obtain.
Embodiment 4 (microcapsules)
By ALA powder 7%; Lactoferrin powder 70%; Maltodextrin 10%; PURE WHEY 13%; After first ALA powder and lactoferrin powder being mixed in proportion, with the mixed liquor of maltodextrin and PURE WHEY, carry out embedding, after low temperature drying, then carry out packing, obtain.
Embodiment 5 (pulvis)
By ALA powder 22.5%; Lactoferrin powder 67.5%; Fruit powder 2%; Inulin 8%; After mixing in proportion, carry out packing, obtain.
Embodiment 6 (soft capsule)
By ALA powder 22.5%; Lactoferrin powder 7.5%; Beeswax 4%; Lecithin 3%; Vegetable oil 63%; Mix in proportion to obtain content; Separately, with gelatin, glycerine, water=in proportion be mixed and made into glue at 1: 0.4: 1, with automatic soft capsule pellet press, carry out pelleting, after drying and get final product.
Embodiment 7 (solid beverage)
By ALA powder 20%; Lactoferrin powder 2%; Xylo-oligosaccharide 13%; Oligoisomaltose 15%; Glucose 30%; Milk powder 20%; After mixing in proportion, carry out packing, obtain.
Embodiment 8 (tablet)
By ALA powder 15%; Lactoferrin powder 0.6%; Galactooligosaccharide 20%; Maltodextrin 64.4%; After mixing in proportion, through granulating, after drying, carry out again compressing tablet, obtain.
Embodiment 9 (dairy products)
By a-LA powder 10%; Lactoferrin powder 0.2%; Whole milk powder 11.5%; Water 78.3%; After mixing in proportion, packing and get final product.
Embodiment 10 (beverage)
By ALA powder 0.99%; Lactoferrin powder 0.01%; Vitamin C 0.4%; Cobastab
10.13%; Cobastab
20.12%; Cobastab
60.12%; Glucose 10%; Milk powder 10%; Purified water 78.23%; After mixing makes to be uniformly dissolved fully in proportion, then carry out packing, obtain.
The invention provides the above-mentioned alimentation composition that contains ALA and lactoferrin, the application aspect enhancing immunity.Be below to effect research of the present invention:
Lactoferrin is one of most important bioactivator in milk, and protection body, treatment disease are all played an important role.The multiple biologically actives such as quantity research shows greatly, and it is antibiotic, anti-oxidant, anticancer that lactoferrin has.The health food that can be used for development of new.In baby formula milk powder or baby food, add lactoferrin, can help the infant to resist the microorganisms such as Escherichia coli, reduce baby's common diseases such as diarrhoea that virus causes, improve its immunity.
The nutritive quality of ALA, higher than the milk protein of standard, is not only because it contains the essential amino acid that content is high, also has conditionally essential amino acid, and ALA more can combine with micronutrient.Therefore, the inventor thinks, ALA may be of value to immunity and nervous system, and the growth of the maturation that promotes internal organ and healthy internal organ microbiologic population.
1, experiment material
Sample: the sample that ALA powder, lactoferrin powder make by embodiment 1.
Animal used as test: quality is the mouse of 18～22g left and right, and 90, the male and female dual-purpose, be divided at random 3 and organize greatly, and every large group is divided at random again 3 groups and tests.
Test method: be recommended as 0.01g/kg according to the human body taking dose, so establish that composition is low, high dose is 0.05g/kg and 0.2g/kg (be equivalent to respectively human body recommended amounts 5 times, 20 times), after sample is made into and is subjected to test solution, press to mouse stomach, the control group gavage is with equal-volume distilled water, once a day, continuous 30 days.
2, strengthen the immunity function evaluation method
The mouse spleen lymphocyte transformation experiment of inducing by ConA: mtt assay: serum hemolysin is measured: Hemagglutination Method; Antibody-producting cell detects: Jerne improves slide method; Turnover of Mouse Peritoneal Macrophages is engulfed the chicken red blood cell experiment: half intracorporal method.
3, strengthen the immunity function evaluation result
3.1 the impact that composition produces the mice serum hemolysin
Table 1 composition is on the purify the blood impact of lysin antibody product of Mouse Blood
Annotate
*P<0.05 is compared in expression with control group
Low, high dose group is compared with control group mice as shown in Table 1, and the antibody product has significant difference (P<0.05).
3.2 the impact of composition on the mouse antibodies cellulation
The impact of table 2 composition on the mouse antibodies cellulation
Annotate
*P<0.01 is compared in expression with control group
Low, high dose group is compared with control group mice as shown in Table 2, and the antibody-producting cell number all has significant difference (P<0.01)
3.3 the impact of composition on Turnover of Mouse Peritoneal Macrophages chicken red blood cell ability
Table 3 composition is engulfed the impact of chicken red blood cell ability on Turnover of Mouse Peritoneal Macrophages
Annotate
*P<0.05 is compared in expression with control group
Low, high dose group is compared with control group mice as shown in Table 3, and its peritoneal macrophage has significant difference (P<0.05) to the phagocytic percentage phagocytic index of chicken red blood cell.
3.4 the functional evaluation result is shown by above-mentioned experimental result: in the experiment of mice serum hemolysin test, antibody-producting cell test experience, Turnover of Mouse Peritoneal Macrophages, engulf in the chicken red blood cell experiment, its result has significant difference.According to evaluation criterion, can think that composition has the function that strengthens immunity.
2 composition Toxicological evaluations
2.1 material
Sample: the sample that ALA powder, lactoferrin powder make by embodiment 1.
Animal used as test: clean level Kunming mouse and SD rat
2.2 Toxicological evaluation method
Composition is carried out to acute toxicity testing (MTD method), genetoxic experiment and rat and fed experiment in 30 days.Wherein the genetoxic experiment comprises Ames experiment, PCEMNR micronucleus test and mouse sperm deformity experiment.
2.3 Toxicological evaluation result
The acute oral toxicity experiment: the acute oral MTD of SD rat and Kunming mouse all belongs to actual non-toxic type greater than 20g/kg.bw.
Genetoxic experiment Ames experiment: PCEMNR micronucleus test and 3 genetoxic experimental results of mouse sperm deformity experiment are all negative, show that this product is without mutagenesis and teratogenesis.
Rat was fed experiment in 30 days: maximum dose level is 100 times of human body recommended amounts, and this product does not cause the ANOMALOUS VARIATIONS of every important indicators such as rat holistic health biochemical functions and organ-tissue morphology.
Above-described is only the preferred embodiment of the present invention; it should be pointed out that the those of ordinary skill in the art, under the prerequisite that does not break away from core technology feature of the present invention; can also make some improvement, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (1)
1. a pulvis that contains the alimentation composition of ALA and lactoferrin, is characterized in that preparing by following method: by ALA powder 22.5%; Lactoferrin powder 67.5%; Fruit powder 2%; Inulin 8%; After mixing in proportion, carry out packing, obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100412784A CN102551073B (en) | 2012-02-22 | 2012-02-22 | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100412784A CN102551073B (en) | 2012-02-22 | 2012-02-22 | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102551073A CN102551073A (en) | 2012-07-11 |
| CN102551073B true CN102551073B (en) | 2013-11-20 |
Family
ID=46398720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100412784A Active CN102551073B (en) | 2012-02-22 | 2012-02-22 | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102551073B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103734745B (en) * | 2013-12-18 | 2015-05-06 | 武汉市元大生物科技有限公司 | Method for preparing compound microcapsule of high-concentration lactoferrin and lactobacillus acidophilus |
| WO2015154254A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
| WO2015154262A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
| WO2015154260A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
| CN105286022A (en) * | 2015-10-12 | 2016-02-03 | 十堰天翔生物科技股份有限公司 | Compound protein powder rich in content of essential amino acids and reasonable in composition and preparation method of compound protein powder |
| CN106418553A (en) * | 2016-08-24 | 2017-02-22 | 方雅悯 | Milk gamma globulin immune capsules and preparation method thereof |
| CN109938104A (en) * | 2017-12-21 | 2019-06-28 | 刘爱民 | Agree in one kind containing a piece of |
| CN110115294A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of lactoferrin particle health food and its production method |
| CN110115387A (en) * | 2018-02-05 | 2019-08-13 | 常州英莱克斯生物工程有限公司 | A kind of lactoferrin piece health food and its production method |
| CN108541952A (en) * | 2018-04-10 | 2018-09-18 | 李钟� | A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity |
| CN108813632A (en) * | 2018-07-13 | 2018-11-16 | 李钟� | A kind of alimentation composition and its application containing lactoferrin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1629183A (en) * | 2004-09-03 | 2005-06-22 | 王秀英 | Active lactoprotein extracted from yak milk and its extraction method and use |
| CN101341908A (en) * | 2007-05-28 | 2009-01-14 | 昆明雪兰牛奶有限责任公司 | High-protein milk |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647490B (en) * | 2009-09-14 | 2011-12-28 | 内蒙古蒙牛乳业（集团）股份有限公司 | Yoghurt with active ingredients and heat-sensitive materials in cow milk being preserved and production method thereof |
-
2012
- 2012-02-22 CN CN2012100412784A patent/CN102551073B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1629183A (en) * | 2004-09-03 | 2005-06-22 | 王秀英 | Active lactoprotein extracted from yak milk and its extraction method and use |
| CN101341908A (en) * | 2007-05-28 | 2009-01-14 | 昆明雪兰牛奶有限责任公司 | High-protein milk |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102551073A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102551073B (en) | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition | |
| CN105360319A (en) | Child development formula milk powder and preparation method thereof | |
| CN102422900A (en) | Formula milk powder for promoting absorption of fatty acid and calcium and preparation method thereof | |
| CN102940154B (en) | Feed for improving productivity of newly born dairy calf | |
| CN106578092A (en) | Children milk powder and making method thereof | |
| CN103315299A (en) | Health-care food with function of enhancing immunity and memory | |
| CN102783564A (en) | Application method for Chinese herbal medicine during perinatal period of dairy cow | |
| CN103070242A (en) | Formula goat milk powder for pregnant women and preparation method of formula goat milk powder | |
| CN103039605A (en) | Pregnant woman milk powder capable of restraining early pregnancy reaction and preparation method thereof | |
| CN104304177A (en) | Vitamin A-rich and potassium-rich egg production method | |
| CN105432792A (en) | Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods | |
| CN108813632A (en) | A kind of alimentation composition and its application containing lactoferrin | |
| CN104962392A (en) | Preparation method of chamomile extracts, healthcare milk beverage with chamomile extracts and processing method of milk beverage | |
| CN111919889A (en) | Mother-emulsified infant formula goat milk powder capable of improving immunity and preparation method thereof | |
| CN109198203A (en) | A kind of pig-breeding method | |
| CN102511858A (en) | Thickened red jujube pulp suitable for being taken by pregnant women and manufacturing technology of same | |
| CN105053213A (en) | Milk powder capable of improving infant's immunity and production method thereof | |
| CN102726622B (en) | Nutritional health liquid for porket, and preparation method and application method thereof | |
| CN107789444A (en) | A kind of bright hair vitamine soft capsule prescription of pet dog and preparation method thereof | |
| CN105853459A (en) | Medicinal composition used for sows to prevent and treat diarrhea of newborn piglets, and compound traditional Chinese veterinary medicinal preparation method thereof | |
| CN105192698B (en) | A kind of health food containing leaf of Moringa powder and preparation method thereof | |
| CN108541952A (en) | A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity | |
| CN109223691A (en) | A kind of daily use chemicals ferment and preparation method thereof | |
| CN111298099A (en) | Iron-supplementing composition and preparation method and application thereof | |
| CN1692783A (en) | Donkey-hide gelatin milk, and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: ZHEJIANG KANGNUOBANG HEALTH PRODUCTS CO., LTD. Free format text: FORMER NAME: ZHEJIANG CONBA HEALTH PRODUCTS CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 310052 Binjiang District, Zhejiang Province, Hangzhou Road, No. 568 Patentee after: Zhejiang Kangnuobang Health Products Co., Ltd. Address before: 310052 Binjiang District, Zhejiang Province, Hangzhou Road, No. 568 Patentee before: Zhejiang Conba Health Products Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170116 Address after: 311700 Hangzhou Province, Chunan County, Qiandao Lake high speed railway new eco industrial park road, No. 7 Patentee after: Qiandao Lake Hangzhou Kang Nuobang health products Limited Address before: 310052 Binjiang District, Zhejiang Province, Hangzhou Road, No. 568 Patentee before: Zhejiang Kangnuobang Health Products Co., Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition Effective date of registration: 20200313 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co., Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT Co.,Ltd. Registration number: Y2020330000098 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210317 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT Co.,Ltd. Registration number: Y2020330000098 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A nutritional composition containing a - lactalbumin and lactoferrin and its application Effective date of registration: 20210324 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT Co.,Ltd. Registration number: Y2021330000205 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210908 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT Co.,Ltd. Registration number: Y2021330000205 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method containing a- Nutritional composition of lactalbumin and lactoferrin and its application Effective date of registration: 20211112 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT CO.,LTD. Registration number: Y2021330002242 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220308 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT CO.,LTD. Registration number: Y2021330002242 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method containing a- Nutritional composition of lactalbumin and lactoferrin and its application Effective date of registration: 20220309 Granted publication date: 20131120 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU QIANDAOHU CANOBANK HEALTH PRODUCT CO.,LTD. Registration number: Y2022330000317 |